195 related articles for article (PubMed ID: 26286294)
1. Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Med Res Rev; 2016 Mar; 36(2):248-99. PubMed ID: 26286294
[TBL] [Abstract][Full Text] [Related]
2. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
3. Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An
Farsani FM; Ganjalikhany MR; Vallian S
Curr Cancer Drug Targets; 2017; 17(7):657-668. PubMed ID: 27834128
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, bioevaluation of LFC- and PA-tethered anthraquinone analogues of mitoxantrone.
Xie XW; Liu ZP; Li X
Bioorg Chem; 2020 Aug; 101():104005. PubMed ID: 32599362
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of anticancer drugs targeted to topoisomerase II.
Hande KR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):173-84. PubMed ID: 9748560
[TBL] [Abstract][Full Text] [Related]
7. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
8. Influence of nucleotide excision repair on mitoxantrone cytotoxicity.
Rocha JC; Busatto FF; de Souza LK; Saffi J
DNA Repair (Amst); 2016 Jun; 42():33-43. PubMed ID: 27135788
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
[TBL] [Abstract][Full Text] [Related]
10. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
[TBL] [Abstract][Full Text] [Related]
11. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Hazlehurst LA; Argilagos RF; Emmons M; Boulware D; Beam CA; Sullivan DM; Dalton WS
Cancer Res; 2006 Feb; 66(4):2338-45. PubMed ID: 16489039
[TBL] [Abstract][Full Text] [Related]
12. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
Karki R; Park C; Jun KY; Kadayat TM; Lee ES; Kwon Y
Eur J Med Chem; 2015 Jan; 90():360-78. PubMed ID: 25437622
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
Osheroff N; Corbett AH; Robinson MJ
Adv Pharmacol; 1994; 29B():105-26. PubMed ID: 8996604
[No Abstract] [Full Text] [Related]
15. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.
Marinello J; Delcuratolo M; Capranico G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404148
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
17. Chromosome mediated gene transfer of drug resistance to mitoxantrone.
Hazlehurst LA; Gros P; Dalton WS
Anticancer Res; 1998; 18(2A):1005-10. PubMed ID: 9615755
[TBL] [Abstract][Full Text] [Related]
18. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a novel anthracycline derivative.
Koeller J; Eble M
Clin Pharm; 1988 Aug; 7(8):574-81. PubMed ID: 3048848
[TBL] [Abstract][Full Text] [Related]
20. Amido analogs of mitoxantrone: physico-chemical properties, molecular modeling, cellular effects and antineoplastic potential.
Zagotto G; Moro S; Uriarte E; Ferrazzi E; Palù G; Palumbo M
Anticancer Drug Des; 1997 Mar; 12(2):99-112. PubMed ID: 9113065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
